PHARMACEUTICAL FORMULATIONS SEEKS MEETING WITH FDA ON SODIUM ASPIRIN
This article was originally published in The Tan Sheet
PHARMACEUTICAL FORMULATIONS SEEKS MEETING WITH FDA ON SODIUM ASPIRIN in response to FDA's denial of monograph eligibility in June 1993. In a Feb. 14 letter to the agency, Pharmaceutical Formulations outside counsel Robert Pinco (Washington, D.C. offices of Akin, Gump, Strauss, Hauer & Feld) asserted that FDA's decision not to include sodium aspirin in the OTC internal analgesic final rule "is erroneous, arbitrary, in conflict with agency policy and principles of science and must be reconsidered and reversed."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC